...trial, which was launched by Pfizer Inc. in 2011. Pfizer’s Phase IV REMOTE study of Detrol LA...

...Teva launched an authorized generic of Pfizer's Detrol LA tolterodine ER in the U.S. Detrol LA, an extended-release muscarinic...
...frequency. Teva declined to disclose the price of the generic. Pfizer reported combined Detrol and Detrol LA...
...the nine months ended Sept. 30, 2013; the pharma does not break out sales for Detrol LA...

...buprenorphine/naloxone Reckitt Benckiser/MonoSol Rx CVS Immunosuppressants, calcineurin inhibitors(transplant) Hecoria tacrolimus Novartis CVS Urinary antispasmodics (OAB/incontinence) Detrol LA...

...Jersey claiming that Mylan's ANDA for a generic version of Pfizer's overactive bladder (OAB) drug Detrol LA...
...earlier under undisclosed circumstances, and March 1, 2014, pending approval. The basic product patent for Detrol LA...
...the formulation patents expire in December 2020. The companies declined to disclose details. Pfizer markets Detrol LA...

...Phase IV trial in 642 patients with OAB who had a suboptimal response to Detrol LA tolterodine ER...
...to initially receive open-label, once-daily Detrol LA for 2 weeks. Patients with a suboptimal response to Detrol LA...
...rights to Toviaz from Schwarz Pharma AG , now part of UCB. Pfizer also markets Detrol LA...

...discontinued enrollment in the double-blind, placebo-controlled, U.S. Phase IV REMOTE trial evaluating daily 4 mg Detrol LA...
...by replicating the results of a previously completed 8-week, double-blind, European Phase IV trial of Detrol LA...
...urge urinary incontinence, urgency and frequency. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Detrol LA tolterodine ER (Detrol LA...

...began the double-blind, placebo-controlled, U.S. Phase IV REMOTE trial to evaluate daily 4 mg Detrol LA tolterodine ER...
...by replicating the results of a previously completed 8-week, double-blind, European Phase IV trial of Detrol LA...
...of urge urinary incontinence, urgency and frequency. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Detrol LA tolterodine ER...

...Phase II trial in 120 female patients to compare 2 mg THVD-201 vs. 2 mg Detrol LA...
...in an open-label extension period after 16 weeks. Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Detrol LA...

...THVD-201 was safe and improved salivary output and related dry mouth side effects compared to Detrol LA...

...in 32% of females and 35% of males. Branded drugs included in the study were Detrol LA...
...U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Detrol LA tolterodine ER...